Tony McHale standing in his garden, smiling.

Help every man with prostate cancer

Give the gift of research to help every man with prostate cancer live longer, healthier lives.

Donate now

Tony McHale (pictured above) discovered he had an alteration in the BRCA2 gene at the age of 61, putting him at a much higher risk of developing prostate cancer. Shortly after, Tony joined the IMPACT study at the ICR, which investigated whether regular screening would lead to earlier diagnosis of aggressive forms of the disease. Around 18 months later, the screening revealed Tony had prostate cancer. 

"Being involved in the IMPACT study saved my life. If I hadn't taken part, I'd never have known I had prostate cancer. As far as I was aware, I didn't have any symptoms – and the sooner the disease is detected and treated, the better the chances are of survival." – Tony

Godfrey's prostate cancer story

 

DJ and music promoter, Godfrey Fletcher, found out he had prostate cancer in 2015 at the age of 47, shortly after his father had also been diagnosed.

"I was so lucky that my cancer was picked up at a very early stage. I was young and fit, with no symptoms. A year after my treatment finished, I was told it had been successful. My dad wasn't so fortunate. He was diagnosed with advanced prostate cancer and passed away at 80. His experience, and mine, showed me the importance of early diagnosis."

Why we need more research into prostate cancer

We're proud of the research advances we've made over the last 20 years. Our scientists discovered the drug abiraterone; identified genetic variants that influence risk of developing the disease; and pioneered new, more precise forms of radiotherapy. But despite our research advances, some prostate cancers remain difficult to treat. This includes those diagnosed at a later stage and those more aggressive tumours, which can spread quickly and evolve to resist treatment.

That's why we urgently need better ways to detect prostate cancer earlier, predict drug resistance, and develop smarter, more personalised treatments. Your gift will help our world-leading researchers unravel the complexity of prostate cancer, to give men precise and personalised care with the right treatments at the right time, to live longer and healthier lives.

Professor Eeles's goal is to develop new tests that could be used in prostate cancer screening, helping to identify men at a higher risk. Her team showed that a simple saliva test, carried out at home, was more accurate at identifying future risk of prostate cancer for some men than the current standard blood test. 

Building on this success, they recently launched a major new study to find out whether an improved version of this test – now suitable for more diverse groups, including Black men and younger men – can help detect more cancers earlier in men at higher risk. 

Tackling drug resistance

Our research underpinned the development of olaparib, a drug that revolutionised treatment for people with BRCA-related cancers. In a recent study, Professor Johann de Bono's team showed that changes which can be spotted with a simple blood test can reveal how long a prostate cancer patient will respond to olaparib. 

The ability to predict when – and how – patients will stop responding to olaparib could help doctors personalise treatment, and in the future, guide the development of new drugs to outsmart resistance – keeping us one step ahead of prostate cancer.

Professor Johann de Bono in the laboratory, smiling.

Creating smarter, kinder treatments for every man

Our scientists are at the forefront of precision cancer medicine – developing more effective treatments with fewer side effects.

Laboratory studies co-led by Dr Adam Sharp and Professor Johann de Bono showed that NXP800 – a new drug which targets a ‘master switch’ that cancer cells hijack to support their growth – slowed prostate cancer cell growth. This innovative drug could potentially also benefit men with advanced prostate cancer that has stopped responding to standard hormone therapy.

A study co-led by Professor Emma Hall has found that men with intermediate-risk, localised prostate cancer can be treated just as effectively with five sessions of higher-dose radiation therapy as with several weeks of standard treatment. Using stereotactic body radiotherapy (SBRT), which targets tumours with pinpoint accuracy, patients can receive a highly effective treatment with far fewer hospital visits. 

A study co-led by Professor Nick James has shown that a new artificial intelligence (AI) test can select which men with high-risk prostate cancer that has not spread will require the life-extending drug abiraterone. In the STAMPEDE trial, the team found that three out of four men could be spared unnecessary treatment, making the drug – discovered by our scientists – more affordable for the NHS.

Your gift can help every man with prostate cancer live longer, healthier lives

Help someone's dad, grandad, brother, uncle, partner, or friend survive prostate cancer. Your support will help fund life-saving research – so that every man can spend more precious time with their loved ones.

Make a donation

Your gift of research can help transform the lives of every man with prostate cancer.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

Your gift of research can help transform the lives of every man with prostate cancer.
With GiftAid you'll also be able to add 25% at no extra cost to you

Please choose a donation amount.

 Related news and blogs

05/01/26 - by

In April 2019, I went on a journey - not one I expected to go on or even particularly wanted to go on, despite being an enthusiastic traveller. But in life we are often taken down unexpected paths. I’m a committed mason of over 40 years and have always been very active in my lodges and province. When a local prostate cancer charity was chosen as the charity for the Masonic year, I went along to a screening session at a local Masonic centre.

I was 58 at the time and didn’t really think anything of it. I was quite fit and healthy, and certainly didn’t think I had any of the main symptoms of prostate cancer.

Then I received an e-mail with the results of a blood test that had been conducted to assess the levels of a protein called prostate specific antigen (PSA). They used a traffic light system to categorise the results, and my PSA result was red. My score was 299.4. For a man my age, it should have been 4.0 or below. I started shaking, almost going into shock. I read the e-mail again. ‘It must be a mistake’, I thought.

As advised in the e-mail, I immediately went, head spinning, to my GP surgery and managed to get an emergency appointment once I had told the receptionist my news.

“I’ll be ok,” I told myself, ‘the test is not fool proof, I’ve got no symptoms.” A sleepless night ensued - one of many.

Dave is wrapped up warm wearing a hat and scarf, surrounded with winter lights

 

“I was determined to be positive”

After seeing my GP, I was fast-tracked through to a urologist at Royal Hampshire County Hospital, Winchester. I was told I probably had prostate cancer, and I was then booked in for an MRI scan, a PET scan and biopsy.

I went to all my appointments with much trepidation and fear. But without fail, every single member of NHS staff I came into contact with was fantastic - compassionate, professional, knowledgeable, friendly, happy and empathetic. I cannot thank them enough for the way they looked after me and continue to do so.

I was eventually diagnosed with stage 4 aggressive advanced metastatic prostate cancer. My Gleason score was 4 + 4 = 8. Ten is the maximum score you can have.

I had taken a good friend along to the appointment for support and afterwards we went to have a beer. It was a chance for me to message my family and friends, to break this very difficult and painful news. It was devastating, but I was determined to be positive. ‘I’m still alive’, I thought. I was going to have treatment and tackle this unwanted ‘squatter’ face on, the best I could.

Dave is sitting in a treatment chair attached to a drip

 

“My oncologist was very knowledgeable and empathetic”

It was hard telling people, but I received so much support from family, friends, former colleagues and lodge groups.

A few people said, “Oh, it’s only prostate cancer, you will be alright! They can sort that out…” All I could think was, ‘Maybe if it hadn’t spread…’

A few weeks after seeing my urologist, I received a letter to go and see my appointed oncologist – a lovely doctor, very knowledgeable and empathetic.

She explained a little more about my cancer, showed me my scans, explained where it had spread, told me of the support available to me and finally addressed a key question I had: life expectancy.

She told me, “On average you have a three-to-five-year survival rate.” - I still remember thinking, 'three to five years left with your family, your friends and loved ones! Just let that sink in!’

Had it been caught sooner, before it had escaped from my prostate, the prognosis would have been a lot better.

My oncologist said, “We cannot cure you, but we can control it, and we’ll throw the kitchen sink at it, due to your health and age.” Thankfully I was in good health and relatively young.

“I agreed to go on the STAMPEDE trial”

My initial treatment was hormone therapy that caused side effects like hot flushes, night sweats and weight gain. It also affected my libido and sexual function.

I agreed to go on the STAMPEDE trial, which aimed to investigate the best treatment for men with newly diagnosed advanced prostate cancer.

From 23 September 2019 I had a course of chemotherapy – docetaxel, every three weeks for six cycles, with my last one on 6 January 2020.

I then took a little break from the chemo to have 20 blasts of radiotherapy - one blast for 10 – 15 minutes every day except weekends.

The afternoon after my first chemo session, my trials nurse phoned to tell me that my PSA score from my recent blood tests was now 1.6, down from 299.4. It meant the hormone treatment was working, in just over two months.

I was also sent for a bone scan to check if the cancer had spread to my bones- luckily it hadn’t!

It was a trying time, but with the help and support of my family and friends, I got through it.

About three weeks after my last chemo session on 6 January 2020, I had a CT scan and was told the chemo had done what they had expected it to do! My PSA score was much lower and continued to drop.

For many years I had worked at as a Parks and Open Spaces Manager, and my former work team and friends sent me a rota they had compiled to take me to hospital in Basingstoke for my radiotherapy. It was lovely gesture and one I was very humbled and grateful for.

“My friends and neighbours helped me through lockdown”

Leading up to my last week of radiotherapy though, another dark and worrying cloud was looming over the horizon -  Covid-19 was becoming more prevalent in the UK.

I was clinically vulnerable so had to self-isolate, but I continued to have phone consultations with my oncology team. They were pleased with my progress and my PSA continued to drop until it was undetectable.

My friends and neighbours were brilliant during lockdown, doing my shopping and ensuring I was ok, keeping me sane and having social distanced garden meets. One very close friend and I met every Sunday afternoon for drinks in the garden four metres away from each other!

As the world started to open up, I slowly began to do a little more – daily walks, socially-distanced walking meetings with my clients and going to see friends outdoors at home, restaurants and in their gardens.

Since then, my PSA readings have remained low. I continue with my hormone implants, blood tests and oncology consultations every three months.

I’ve always loved to travel and have an interest in both world wars. As a young man I worked for the Commonwealth War Graves commission in Passchendaele, Flanders and the Netherlands as a Head Gardener. In recent years, I have had some fantastic and memorable times in Scotland, Belgium, Germany, Holland, Menorca, Denmark to name but a few. After working for local authorities, I now work for myself as a consultant in parks, open spaces and land management.

Dave in a bluebell wood with a female friend holding a small dog

 

“I was proud to have been on the STAMPEDE trial”

I want to talk about what happened to me because if I can save even one man from going through what I have, I will do anything I can.

The treatment is hard and unrelenting. I’ve learnt to live with the side effects of the ongoing hormone treatment that I’m having - for example, I have a hand fan and carry a small flannel to help with hot flushes. I have neuropathy in my feet so have found comfortable shoes that help with that. It’s about learning to adapt to my new life and make changes.

Further research is needed to find better ways to test for and treat prostate cancer. I was proud to have been on the STAMPEDE trial.

We also need more accurate and effective ways of diagnosing men at an early stage. I was adopted so I didn’t know whether there was any prostate cancer in my family.

“I’m determined to just live life to the full”

It’s been over six years since I was diagnosed – so I’ve now made it beyond the three to five year prognosis I was originally given. Going for that PSA test saved my life - the cancer hadn’t gone into my bones. If it had spread further, my prognosis could have been 12 months or even less.

Now when I’m asked about the cancer, I say, “It’s just sleeping.” Sometimes people say to me, “You must be pleased it’s gone”, and I think, “Errrr, no it hasn’t!” Because to me, it is just sleeping. And I hope it stays that way.

No one on this earth knows what’s round the corner. I’m keeping  busy, still running my consultancy business, out most days for various Masonic meetings around the country and abroad, travelling, my usual trips to the Chelsea Flower Show, meeting friends, going to the theatre, having a few beers or wine and dining out, and of course spending precious time with my many friends and family.  I am determined, to the bitter end, to just live life to the full - after all, life is for living.